Shayna E. Sacks

Partner

As a partner in the Napoli Shkolnik PLLC law firm, Shayna E. Sacks specializes in pharmaceutical litigation. As a distinguished personal injury attorney, she focuses her nationwide practice on obtaining the best results for clients in the areas of mass tort litigation, including pharmaceutical products liability, personal injury, medical malpractice, and medical device liability cases. She serves as Plaintiffs’ Liaison Counsel in the In Re: Plavix Product Liability and Marketing Litigation by the Honorable Freda L. Wolfson of the United States District Court, District of New Jersey.

Prior to joining Napoli Shkolnik PLLC, Ms. Sacks worked at Napoli Bern Ripka Shkolnik LLP, with a concentration in pharmaceutical products liability litigation. Previously, she worked at Baker Sanders Barshay Grossman Fass Muhlstock & Neuwirth, LLC, in their no-fault litigation department. Earlier in her career, Ms. Sacks worked at Rheingold, Valet, Rheingold, Shkolnik & McCartney, LLP, and Lewis Saul & Associates, focusing on pharmaceutical products liability, automobile, medical device, and medical malpractice litigation. While attending law school, she interned with the Legal Aid Society, Federal Defenders Division, Southern District of New York.

  • Bar Admissions
    • New York
    • United States District Court, Southern District of New York
    • United States District Court, Eastern District of New York
    • New Jersey
    • United States District Court, District of New Jersey
    • Connecticut
  • Education
    • New York Law School, J.D.
    • American University, B.A.
  • Awards and Honors
  • Professional Affiliations
    • American Bar Association
    • American Association of Justice (AAJ), The Toxic, Environmental, and Pharmaceutical Torts (STEPS) Group
    • Brooklyn Women’s Bar Association (BWBA)
    • New York Women’s Bar Association (NYWBA)
  • Speaking Engagements
    • Speaker, “The Appropriateness of Nuisance as a Remedy”, Perrin Conferences: The Opioid Litigation Conference (June 28, 2018)
    • Speaker, “Opioids: Science, Medicine & Litigation”, HB Litigation Conferences presents Mass Tort Med School: Emerging medical & litigation issues for plaintiff attorneys (May 9 -11, 2018)
    • Featured Speaker, “The Opioid Crisis: Where Are We?”, Safe America Foundation’s 2018 World Spring Symposium (April 2018)
    • Speaker, “State Court Opioid Litigation Updates & Liability Theories”, HarrisMartin’s Opioid Litigation Conference (March 2, 2018)
    • Speaker, “Onglyza and Kombiglyze: Venue and Case Selection Criteria”, HarrisMartin’s MDL Conference: Onglyza, Opioid & Sorin 3T Heater-Cooler System Litigation (January 24, 2018)
    • Faculty Member, “Opioid Crisis: Claims, Damages & Science”, HB Litigation Conferences (January 2018)
    • Conference Co-Chair, “Plaintiff Opioid MDL Conference”, HarrisMartin Publishing (January 2018)
    • Featured Panelist, “Mass Torts on State and Federal Cooperation” & “Litigation Group Update: Opioids,” Mass Tort Seminar 2017 presented by the Colorado Trial Lawyers Association (CTLA)
    • Featured Speaker, “The Opioid Epidemic,” Safe America Foundation’s 2017 World Safe Summit (October 2017)
    • Featured Speaker, “The Judiciary & MDL and the State Court Consolidations: A Delicate Balance”. Plaintiffs’ Forum on Mass Tort Litigation by Cambridge Forums
    • Featured Panelist, “Current Landscape of Opioid Litigation”, National Opioid Litigation Conference: HarrisMartin Publishing
    • Speaker, “The History of Bristol-Myers Squibb Co. v. Superior Court: How Did It Get Here So Fast,” HarrisMartin California Mass Tort and Class Action Litigation Conference: The Impact of Daimler and BMS-Plavix
  • Media Appearances
  • Court Appointments
    • Plaintiffs’ Steering Committee, In Re: Proton-Pump Inhibitor Products Liability Litigation (MDL 2789)
    • Member, Taxotere – Privilege, Confidentially and Protective Orders Committee (MDL 2740)
    • Plaintiffs’ Liaison Counsel, In Re: Plavix Product Liability and Marketing Litigation (MDL 2418)
  • Representative Cases and Settlements of Note

    In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation: Ms. Sacks’ clients participated in the $650 Million Pradaxa Master Settlement Program for compensation for their bleeding injuries caused by the blood thinner Pradaxa.

  • Other Experience
    • Napoli Bern Ripka Shkolnik LLP
    • Baker Sanders, LLC, formerly known as, Baker Sanders Barshay Grossman Fass Muhlstock & Neuwirth, LLC
    • Rheingold, Valet, Rheingold, McCartney & Giuffra LLP, formerly known as Rheingold, Valet, Rheingold, Shkolnik & McCartney LLP
GET HELP NOW